Rearrangements within DMBT1 are frequently discovered in multiple tumors (24, 25), and mutated FOXO1 is a known marker for decreased overall survival in DLBCL patients associated with failure to achieve event-free survival at 24 months (EFS24) after diagnosis (14, 26). Here, DMBT1 is linked to diffuse large B-cell lymphoma.